INTRODUCTION {#S1}
============

B cell development depends on successful gene rearrangements at the immunoglobulin (Ig) loci to ensure that mature B cells express a diverse repertoire of antibodies. During this process, a VDJ~H~ joint is assembled at the Ig heavy (*Igh*) chain locus in pro-B cells, which, if in the correct reading frame, leads to the expression of an Igμ protein. Igμ assembles with surrogate light chains to form a surface pre-B cell receptor (pre-BCR), which guides the pro-B cell to pre-B cell transition. Following signaling by the pre-BCR, pre-B cells undergo clonal expansion and subsequent rearrangement of the Ig light (*IgL*) chain loci. Successfully rearranged light chains assemble with an Igμ chain, forming a surface BCR, and drive the progression to immature B cells that will form the reservoir of long-lived mature B cells ([@R16]).

The process of V(D)J recombination presents inherent risks to the organism because of the generation of double-strand breaks and subsequent non-homologous end joining of DNA fragments at the *Ig* loci. Thus, numerous mechanisms exist to ensure the proper generation of a clonal surface BCR on B cells while preventing deleterious events. These include the sequential rearrangement of *Ig* loci, with several checkpoints along the sequential development to assess rearrangement status, and the programming of developing B cells for either clonal expansion or apoptosis, depending on pre-BCR and BCR signaling cues ([@R27]). While extensive work has elucidated many of these mechanisms, our understanding of the molecular pathways critical for B cell development remains fragmentary.

Polycomb group (PcG) proteins are a group of regulatory factors that form multimeric protein complexes and are critical for maintaining cell identity and cell proliferation by modifying chromatin structure and silencing genes ([@R40]). Polycomb repressive complex 1 (PRC1) and polycomb repressive complex 2 (PRC2) were the earliest complexes described, although more recent work has identified both alternative and novel polycomb complexes. The core components of PRC1 consist of one member of each CBX, HPH, PCGF, and RING1 protein family, which monoubiquitinate histone H2A on lysine 119 (H2AK119), whereas the core components of PRC2 are EED, Suz12, EZH1/2, and RBBP4/7, which methylate H3K27 ([@R6]; [@R41]). PRC1 and PRC2 are thought to cooperate to regulate gene expression, because PRC2 deposition of H3K27me3 recruits PRC1 through its CBX family member ([@R3]). However, inactivation of core PRC2 factors in mammalian cells only partially affects PRC1 recruitment to its target loci and minimally changes global H2AK119ub levels, suggesting that PRC2-independent mechanisms exist for PRC1 recruitment ([@R44]).

Through genetic studies in the mouse, it became apparent that PcG proteins are critical for B cell lymphopoiesis. EZH2 regulates distal V~H~ gene usage during V~H~-DJ~H~ recombination and prevents *IgL* loci rearrangement in pro-B cells ([@R24]; [@R43]). The PRC1 component BMI1, also known as PCGF4, is required for normal lymphocyte development at least partly through the repression of the *Ink4/Arf* locus, which encodes the two tumor suppressor proteins, p16^INK4A^ and p19^ARF^ ([@R4]; [@R31]). In developing T cells, BMI1 prevents premature p19^ARF^-mediated stabilization of p53 to promote the proliferation and survival of progenitor T cells in response to pre-T cell receptor (TCR) signaling ([@R28]). However, *Bmi1*^−/−^ *Ink4a/Arf*^−/−^ mice still exhibit defective B cell lymphopoiesis, suggesting that BMI1 functions partly through *Ink4a/Arf*-independent mechanisms during B cell development ([@R31]).

We found that BMI1 is required for pro-B cells to differentiate into pre-B cells in a cell-autonomous manner. Loss of BMI1 results in the upregulation of p53 target genes in pro-B cells, precluding the expansion of these cells at the large pre-B stage. Furthermore, expression of rearranged *Igh* genes and production of the Igμ chain are impaired in *Bmi1*^−/−^ pro-B cells. Accordingly, introduction of a pre-rearranged *Igh* allele partially restored B cell development in *Bmi1*^−/−^ mice. Altogether, these results identify a critical role for BMI1 in B cell development through the regulation of rearranged *Igh* gene expression and expansion of pre-B cells.

RESULTS {#S2}
=======

BMI1 Is Required for the Pro-B Cell to Pre-B Cell Transition {#S3}
------------------------------------------------------------

Previous studies have identified BMI1 as essential for B cell development in the mouse ([@R31]; [@R46]). However, the mechanisms that BMI1 engages to promote B cell development remain unknown. To begin to dissect the function of BMI1 in progenitor B cells, we first assessed its expression levels throughout early B cell development using data acquired through the Immunological Genome Project ([@R15]; [@R32]). *Bmi1* is highly expressed in pro-B cells and large pre-B cells and is downregulated as large pre-B cells transition into small pre-B cells ([Figure S1A](#SD1){ref-type="supplementary-material"}). The expression of *Cdkn2a*, which encodes the tumor suppressor proteins p16^INK4A^ and p19^ARF^ and is repressed by BMI1, inversely correlates with *Bmi1* expression at the pro-B cell to pre-B cell transition ([Figure S1A](#SD1){ref-type="supplementary-material"}). This correlation disappears in mature B cells, likely pointing to a more critical role for a *Bmi1-Cdkn2a* axis at the pro-B cell to pre-B cell transition. The high expression of *Bmi1* and the resulting repression of *Cdkn2a* early in B cell development are reminiscent of what has been observed in early T cell development, in which BMI1 represses p19^ARF^ to prevent apoptosis in proliferating DN3 T cells ([@R28]). Furthermore, the inverse correlation of *Bmi1* and *Cdkn2a* levels is consistent with studies demonstrating a modest rescue of B cell development in *Bmi1*^−/−^ *Ink4a/Arf*^−/−^ mice ([@R28]; [@R31]).

To further probe BMI1's function in early B cell development, we determined the frequency and numbers of early B cell progenitors in *Bmi1*^+/+^ and *Bmi1*^−/−^ mice. The bone marrow of *Bmi1*^−/−^ mice was devoid of B cells, correlating with the accumulation of pro-B cells and their failure to differentiate into pre-B cells ([Figures 1A and 1B](#F1){ref-type="fig"}; [Figure S1B](#SD1){ref-type="supplementary-material"}). The differentiation block at the pro-B cell to pre-B cell transition resulted in drastically fewer mature B cells in the peripheral blood and spleen of *Bmi1*^−/−^ mice and a corresponding increase in the frequency of CD11b^+^ myeloid cells ([Figures 1C and 1D](#F1){ref-type="fig"}). Consistent with previous reports ([@R46]), we observed a drastic reduction in the cellularity of various hematopoietic organs of *Bmi1*^−/−^ mice as a consequence of the overall reduction in lymphocyte numbers ([Figure S1C](#SD1){ref-type="supplementary-material"}).

Reduced Igμ Chain Expression in *Bmi1*^−/−^ Pro-B Cells {#S4}
-------------------------------------------------------

The pro-B cell to pre-B cell transition and subsequent expansion of large pre-B cells depend on the successful rearrangement of the *Igh* locus, the expression of Igm chain, the assembly of a pre-BCR on the surface of the cell, and signaling downstream of the pre-BCR. Failure in any of these steps will impair pro-B cell to pre-B cell differentiation ([@R16]). We therefore determined whether BMI1 was required for the expression of Igμ chain in pro-B cells. By intracellular flow cytometry analysis, we observed a decrease in the frequency of pro-B cells expressing Igμ chain in *Bmi1*^−/−^ mice to about half of the levels observed in *Bmi1*^+/+^ mice ([Figure 2A](#F2){ref-type="fig"}). In addition, we observed a decrease in the median Igμ fluorescence intensity in Igμ-expressing pro-B cells from *Bmi1*^−/−^ mice ([Figure 2B](#F2){ref-type="fig"}).

BMI1 Is Dispensable for VDJ~H~ Recombination but Required for Rearranged *Igh* Gene Expression in Pro-B Cells {#S5}
-------------------------------------------------------------------------------------------------------------

We next determined the basis for the reduction in Igμ chain expression in *Bmi1*^−/−^ pro-B cells. This reduction could result from inefficient VDJ~H~ recombination and/or failure to express rearranged *Igh* genes. To assess whether BMI1 inactivation alters VDJ~H~ recombination, we determined the frequency of rearrangement for two V~H~ gene families, V~H~7183 and V~H~J558, in *Bmi1*^+/+^ and *Bmi1*^−/−^ pro-B cells. The V~H~7183 gene family is the most proximal V~H~ family and the V~H~J558 family is the most distal V~H~ family to DJ~H~ genes ([Figure S2A](#SD1){ref-type="supplementary-material"}). Because the PRC2 component EZH2 is required for distal V~H~ gene usage ([@R43]), we tested whether BMI1 similarly enabled distal V~H~ gene usage. On genomic DNA isolated from pro-B cells, we performed semiquantitative PCR using degenerative forward primers that amplify either V~H~7183 genes or V~H~J558 genes and a reverse primer specific to the J~H~3 gene. *Bmi1*^−/−^ pro-B cells and their wild-type counterparts contained comparable levels of DNA that had recombined either V~H~7183 or V~H~J558 genes with DJ~H~ genes ([Figure 2C](#F2){ref-type="fig"}). In addition, we isolated and sequenced individual VDJ~H~ joints from *Bmi1*^+/+^ and *Bmi1*^−/−^ pro-B cells using a promiscuous forward primer that amplifies various genes across all V~H~ families. Again, we observed no difference in the ratio of proximal to distal V~H~ gene usage between *Bmi1*^+/+^ and *Bmi1*^−/−^ pro-B cells, supporting the conclusion that BMI1 is not required for VDJ~H~ recombination in pro-B cells ([Figure 2D](#F2){ref-type="fig"}).

In contrast, when we assessed the expression levels of rearranged *Igh* genes, we observed a drastic reduction in the expression levels of all V~H~ family genes tested in *Bmi1*^−/−^ pro-B cells, consistent with a combined decreased frequency of *Bmi1*^−/−^ pro-B cells expressing Igm and decreased Igμ protein levels in Igμ-expressing *Bmi1*^−/−^ pro-B cells ([Figure 2E](#F2){ref-type="fig"}). The decrease in rearranged *Igh* gene expression was not the result of a generic reduction in expression at the *Igh* locus, because we detected no difference in the expression of D~H~-C~u~ transcripts ([Figure 2E](#F2){ref-type="fig"}). Altogether, these data support a model in which BMI1 is dispensable for VDJ~H~ recombination but is critical for expression of recently rearranged VDJ~H~ genes in pro-B cells.

BMI1 Is Not Required for *Igh* Germline Transcription or *Igh* Contraction {#S6}
--------------------------------------------------------------------------

PRC1 has been shown to regulate high-order chromatin architecture ([@R41]). For RAG complexes to access V~H~ genes and initiate recombination, the surrounding chromatin needs to be accessible ([@R8]; [@R12]). The transcription of *Igh* genes in germline configuration (germline transcription) has been hypothesized to be critical for RAG accessibility to these genes ([@R47]). We therefore first assessed whether BMI1 loss altered the ability of the germline *Igh* loci to be transcribed in pro-B cells as a surrogate assay for chromatin accessibility. However, we did not observe differences in germline transcription for either V~H~7183 or V~H~J558 gene families between *Bmi1*^+/+^ and *Bmi1*^−/−^ pro-B cells ([Figure S2B](#SD1){ref-type="supplementary-material"}). Because we observed that BMI1 modulates the expression of recombined *Igh* genes in pro-B cells, and given the impact of chromatin architecture on *Igh* recombination ([@R37]), we next assessed the impact of BMI1 on high-order organization of the *Igh* loci. With 3D microscopy, we determined whether BMI1 is required for *Igh* contraction by using DNA-fluorescence *in situ* hybridization (FISH) probes against the 5′ *Igh* (distal) and 3′ *Igh* (proximal) regions. Consistent with our finding that *Bmi1*^−/−^ pro-B cells efficiently use both proximal and distal V~H~ gene families during V~H~-DJ~H~ joining, the contraction of the *Igh* locus in pro-B cells was not affected by the absence of BMI1 ([Figure S2C](#SD1){ref-type="supplementary-material"}).

A Pre-rearranged *Igh* Allele Restores B Cell Development in *Bmi1*^−/−^ Mice {#S7}
-----------------------------------------------------------------------------

We postulated that if the process of VDJ~H~ recombination at the *Igh* locus affects the expression of rearranged *Igh* genes in *Bmi1*^−/−^ pro-B cells and is responsible for the differentiation block of developing B cells in *Bmi1*^−/−^ mice, the introduction of a pre-rearranged VDJ~h~ allele would rescue B cell development. To test this, we generated *Bmi1*^+/+^ and *Bmi1*^−/−^ mice carrying a recombined VDJ~H~ element inserted into the endogenous *J~H~* locus (*B1.8i*) ([@R42]). Consistent with our hypothesis, introduction of the *B1.8i* allele largely restored B cell development to *Bmi1*^−/−^ animals ([Figures 3A--3C](#F3){ref-type="fig"}; [Figure S3](#SD1){ref-type="supplementary-material"}). The frequencies of immature, mature, and splenic B cells in *Bmi1*^−/−^ *B1.8*^+^ mice were comparable to that of *Bmi1*^+/+^ mice ([Figures 3A--3C](#F3){ref-type="fig"}). Total numbers of *Bmi1*^−/−^ *B1.8*^+^ B cells, while still decreased compared to those of *Bmi1*^+/+^ animals, were drastically increased compared to those of *Bmi1*^−/−^ animals ([Figure S3](#SD1){ref-type="supplementary-material"}). Moreover, when we assessed Igμ expression in pro-B cells, we found that the *B1.8* allele increased the frequency of *Bmi1*^−/−^ pro-B cells expressing Igμ and restored Igμ protein levels in Igμ-expressing *Bmi1*^−/−^ pro-B cells ([Figure 3D](#F3){ref-type="fig"}). Altogether, these data demonstrate that bypassing VDJ~h~ recombination enables *Bmi1*^−/−^ pro-B cells to express Igμ and subsequently differentiate.

BMI1 Loss Results in the Upregulation of p53 Signaling in Pro-B Cells {#S8}
---------------------------------------------------------------------

Although expression of a pre-rearranged *Igh* locus partially rescues B cell development in *Bmi1*^−/−^ mice, *Bmi1*^−/−^ *B1.8i*^+^ bone marrow still contains lower frequencies and numbers of pre-B cells compared to wild-type mice ([Figure 3](#F3){ref-type="fig"}; [Figure S3](#SD1){ref-type="supplementary-material"}). We therefore sought to identify additional mechanisms engaged by BMI1 that control the pro-B cell to pre-B cell transition in developing B cells. We assessed the expression levels of the B cell transcription factors *Pax5* and *Ebf1*, because BMI1 regulates their expression in early progenitors before lymphoid commitment ([@R31]), but we found no difference in their expression between *Bmi1*^−/−^ pro-B cells and their wild-type counterparts ([Figure S4A](#SD1){ref-type="supplementary-material"}). To uncover other altered pathways, we sorted pro-B cells from *Bmi1*^+/+^ and *Bmi1*^−/−^ mice and performed genome-wide expression analysis. Using a false discovery rate (FDR) \< 0.05 as a cutoff for significance, we identified 122 upregulated transcripts and 165 downregulated transcripts in *Bmi1*^−/−^ pro-B cells compared to *Bmi1*^+/+^ pro-B cells ([Table S1](#SD2){ref-type="supplementary-material"}). Numerous p53 targets, including *Bbc3*, *Pmaip1*, *Phlda3*, and *Cdkn1a*, were found among the upregulated transcripts in *Bmi1*^−/−^ pro-B cells ([Figure 4A](#F4){ref-type="fig"}; [Table S1](#SD2){ref-type="supplementary-material"}). Consistent with this observation, gene ontology analysis of upregulated genes in *Bmi1*^−/−^ pro-B cells showed enrichment for pathways associated with apoptosis, proliferation, DNAdamage, and p53 signaling ([Figure S4B](#SD1){ref-type="supplementary-material"}). Similarly, the p53 pathway was enriched in *Bmi1*^−/−^ pro-B cells when analyzed by gene set enrichment analysis (GSEA) ([Figure S4C](#SD1){ref-type="supplementary-material"}). As expected, *p19^Arf^* expression was drastically upregulated in *Bmi1*^−/−^ pro-B cells, demonstrating de-repression of the *Ink4a/Arf* locus, and we confirmed the upregulation of specific p53 target genes, including *Bbc3, Pmaip1, Phlda3*, and *Cdkn1a*, in *Bmi1*^−/−^ pro-B cells from independent animals ([Figure 4B](#F4){ref-type="fig"}). We did not detect changes in *Trp53* transcript levels, suggesting BMI1-dependent post-transcriptional regulation of p53 activity ([Figure 4B](#F4){ref-type="fig"}). Together with previous work demonstrating that deletion of *p19^Arf^* partially restores B cell development to *Bmi1*^−/−^ mice ([@R2]; [@R28]; [@R30]) and our analysis of the expression of *Bmi1* and *Ckdn2a* in progenitor B cells ([Figure S1A](#SD1){ref-type="supplementary-material"}), these findings are consistent with a role for BMI1 in preventing p53 signaling through the repression of the *Ink4a/Arf* locus in developing pro-B cells.

p53 signaling generally results in either apoptosis or cell-cycle arrest ([@R21]). In progenitor T cells, BMI1 prevents apoptosis through the inhibition of the p19^ARF^-p53 pathway ([@R28]). Therefore, we first tested whether increased apoptosis was occurring in developing *Bmi1*^−/−^ B cells. However, we did not observe differences in the frequency of annexin V-positive pro-B cells or pre-B cells in *Bmi1*^−/−^ mice compared to wild-type counterparts ([Figure 4C](#F4){ref-type="fig"}). Following successful VDJ~h~ recombination, signaling through the pre-BCR provides survival cues and promotes the proliferation of large pre-B cells. Following this proliferative burst, pre-B cells become quiescent, differentiate into small pre-B cells, and subsequently rearrange their *IgL* loci ([@R16]). Therefore, we assessed whether the increased p53 signaling prevented the capacity of *Bmi1*^−/−^ large pre-B cells to clonally expand. Large and small pre-B cells can be distinguished by gating on forward scatter within the pre-B cell population. Using this strategy, we observed that *Bmi1*^−/−^ mice have a drastically lower proportion of large pre-B cells in their pre-B cell compartment ([Figure 4D](#F4){ref-type="fig"}). Moreover, the frequency of proliferating cells, as assessed either by DNA content or by bromodeoxyuridine (BrdU) incorporation, in the pre-B cell compartment was decreased in *Bmi1*^−/−^ animals ([Figures S4D and S4E](#SD1){ref-type="supplementary-material"}). We subsequently hypothesized that *Bmi1*^−/−^ *B1.8*^+^ mice may still exhibit decreased pre-B cells numbers ([Figure 3](#F3){ref-type="fig"}; [Figure S3](#SD1){ref-type="supplementary-material"}) due to their inability to clonally expand. Consistent with this hypothesis, there was a comparable reduction both in the proportion of large pre-B cells in the pre-B cell compartment and in the frequency of BrdU-positive pre-B cells between *Bmi1*^−/−^ mice and *Bmi1*^−/−^ *B1.8*^+^ mice ([Figures S4F and S4G](#SD1){ref-type="supplementary-material"}).

Finally, to demonstrate that BMI1 functions upstream of p53 to prevent B cell development, we generated a cohort of animals (*p53^F/F^* *Bmi1*^+/+^, *p53^F/F^* *Bmi1*^+/+^ *Mx1-cre, p53^F/F^ Bmi1*^−/−^ and *p53^F/F^* *Bmi1*^−/−^ *Mx1-cre*, hereafter referred to as *p53^WT^* *Bmi1*^+/+^, *p53^CKO^* *Bmi1*^+/+^, *p53^WT^* *Bmi1*^−/−^, and *p53^CKO^* *Bmi1*^−/−^), in which p53 was acutely deleted following serial injections of poly(I:C). We found that acute p53 deletion partially restored the pro-B cell to pre-B cell transition and the frequency of mature B cells in the periphery in *Bmi1*^−/−^ mice ([Figures 4E and 4F](#F4){ref-type="fig"}). Altogether, these data demonstrate that aberrant p53 signaling caused by BMI1 loss prevents the clonal expansion of large pre-B cells.

BMI1 Is Required for the Pro-B Cell to Pre-B Cell Transition in a Cell-Autonomous Manner {#S9}
----------------------------------------------------------------------------------------

It has previously been postulated that the microenvironment of *Bmi1*^−/−^ mice is defective in supporting B cell lymphopoiesis ([@R31]). To test whether the defects observed in *Bmi1*^−/−^ mice reflected non-cell-autonomous effects of BMI1 on developing B cells, we generated animals in which *Bmi1* is deleted selectively in pro-B cells and their progeny, using the *Mb1-cre* transgene ([@R17]). We confirmed efficient deletion of *Bmi1* and the resulting increased expression of the BMI1-target gene *p19^Arf^* in pro-B cells sorted from *Bmi1^F/F^* *Mb1-cre* mice ([Figure 5A](#F5){ref-type="fig"}). *Bmi1^F/F^* *Mb1-cre* mice presented with reduced total cell numbers in their bone marrow, spleen, and peripheral blood and a roughly 2-fold reduction in the frequency of B cells in the bone marrow ([Figures S5A and S5B](#SD1){ref-type="supplementary-material"}). Consistent with our observations in *Bmi1*^−/−^ mice, cell-autonomous BMI1 loss impaired the pro-B cell to pre-B cell transition, as evidenced by the increased frequency of pro-B cells and the decreased frequency of pre-B cells, in the bone marrow of *Bmi1^F/F^* *Mb1-cre* mice ([Figures 5B and 5C](#F5){ref-type="fig"}). In addition, we observed a reduction in the frequency of B cells in the peripheral tissues of *Bmi1^F/F^* *Mb1-cre* mice ([Figure 5D](#F5){ref-type="fig"}). The fraction of pro-B cells expressing intracellular Igμ chain was reduced in *Bmi1^F/F^* *Mb1-cre* mice ([Figure 5E](#F5){ref-type="fig"}), consistent with the decreased expression of rearranged *Igh* genes ([Figure 5F](#F5){ref-type="fig"}). Again, we observed no difference in the expression of *Pax5* or *Ebf1* in *Bmi1^F/F^* *Mb1-cre* pro-B cells ([Figure S5C](#SD1){ref-type="supplementary-material"}), but we did observe higher levels of p53 target genes ([Figure 5G](#F5){ref-type="fig"}). Finally, subsequent deletion of p53 alleviated the pro-B cell to pre-B cell differentiation block and largely restored the frequency of mature B cells in the periphery to *Bmi1^F/F^* *Mb1-cre* mice ([Figures 5H and 5I](#F5){ref-type="fig"}; [Figure S5D](#SD1){ref-type="supplementary-material"}). Altogether, these data demonstrate that the defects in B cell differentiation observed in *Bmi1*^−/−^ mice are largely recapitulated by cell-autonomous loss of BMI1.

DISCUSSION {#S10}
==========

Prior studies have shown that BMI1 is critical for developing lymphocytes; however, the molecular pathways BMI1 engages to promote B cell development have remained poorly defined, and whether the role of BMI1 in B cell development was cell intrinsic remained to be elucidated ([@R2]; [@R31]; [@R46]). Our analysis identified a cell-autonomous role for BMI1 at two stages during early B cell development. Specifically, BMI1 promotes the expression of rearranged *Igh* genes in pro-B cells and enables large pre-B cell proliferation following pre-BCR signaling through its inhibition of p53 signaling.

In adult stem cells, PRC1 directly binds to and compacts the *Ink4a/Arf* locus, thus repressing the expression of the cell-cycle inhibitors p16^INK4A^ and p19^ARF^ and maintaining stem cell self-renewal capacity ([@R19]; [@R23]; [@R29]; [@R34]). In BMI1 null mice, the failure to develop mature lymphocytes is due to increased expression of p19^ARF^, but not increased expression of p16^INK4A^, as demonstrated by genetic studies in mice ([@R2]). In support of this observation, loss of BMI1 in developing thymocytes results in the upregulation of p19^ARF^ and the premature stabilization of p53, preventing DN3 T cell proliferation downstream of pre-TCR signaling ([@R28]). In agreement with these studies, we found that in developing B cells, the expression level of *Bmi1* is high in proliferating pro-B cells and large pre-B cells and subsequently downregulated in quiescent small pre-B cells and immature B cells. Moreover, loss of BMI1 resulted in the increased expression of p53 target genes in pro-B cells and prevented large pre-B cell expansion following pre-BCR signaling. Our data indicating that genetic inactivation of p53 restored B cell development in *Bmi1*^−/−^ mice, with previous studies showing a partial rescue of peripheral B cells in *Bmi1*^−/−^ *p19*^*Arf*−/−^ double-knockout mice, support a model whereby BMI1 repression of *p19^Arf^* is critical to prevent the stabilization of p53 and premature cell-cycle withdrawal of cycling pre-B lymphocytes.

Past studies had demonstrated that genetic inaction of the *Ink4a/Arf* locus only partially restores B cell development to BMI1 null mice ([@R31]). These observations suggested that BMI1 functioned through unknown *Ink4a/Arf*-independent mechanisms to promote B cell development. It was initially postulated that this may be through non-cell-autonomous pathways, because transplantation studies suggested the bone marrow of *Bmi1*^−/−^ mice was defective at supporting B cell development ([@R31]). We found that in *Bmi1*^−/−^ mice, developing B cells fail to progress through the pro-B cell to pre-B cell transition due to the failure of pro-B cells to express rearranged *Igh* genes. Accordingly, the introduction of a pre-rearranged *Igh* locus largely restored B cell development to BMI1 null mice. The pre-rearranged *Igh* allele did not restore the ability of *Bmi1*^−/−^ large pre-B cells to clonally expand, highlighting the two distinct roles BMI1 plays during early B cell development. Finally, we recapitulated the B cell defects observed in *Bmi1*^−/−^ mice using a pro-B cell-specific Cre transgene, indicating that cell-autonomous mechanisms of BMI1 in progenitor B cells are sufficient to explain the B cell phenotypes observed in BMI1 null mice.

The exact mechanism BMI1 engages to promote the expression of rearranged *Igh* genes remains unclear. The identification that PRC1 is recruited to sites of double-strand breaks (DSBs) and is required for their efficient repair *in vitro* suggests that a similar process may occur during VDJ~H~ recombination ([@R10]; [@R14]; [@R18]). Moreover, BMI1 associates with and recruits factors known to be critical for repair of VDJ~H~ joints, such as ATM, KU70, and 53BP1, to sites of DSBs ([@R10]; [@R33]; [@R45]). However, our data demonstrate that BMI1 is not required for VDJ~H~recombination. In addition, we did not observe an increased frequency of γH2A.X foci at the *Igh* locus in *Bmi1*^−/−^ pro-B cells (data not shown). These differences may stem from the fact that BMI1 is not absolutley required but instead increases the efficiency of DSB resolution, coupled with the higher-sensitivity assays used to detect DSBs in the absence of BMI1 *in vitro* ([@R10]; [@R18]; [@R33]). Alternatively, BMI1 may function downstream of DSB repair to enable to expression of recently damaged loci. Immediately following the generation of DSBs, BMI1 is required to prevent premature transcription of damaged genes through the deposition of H2AK119ub and the inhibition of both the FACT (facilitates chromatin transcription) histone chaperone complex and RNA polymerase II elongation ([@R39]; [@R45]). In the wake of this temporal transcriptional silencing, new uniquely marked histones, such as H3.3, are deposited. The deposition of H3.3 primes recently damaged chromatin and is required for transcription restart ([@R1]). Another study demonstrated that FACT-mediated histone exchange was required for transcription restart following UV damage ([@R7]). However, no studies have demonstrated what happens to transcription restart at sites of DSBs if the initial transcriptional repression does not occur. It is therefore possible that BMI1-dependent transcriptional silencing following the generation of DSBs is required to permit the proper turnover of histones and subsequent re-expression of repaired genes, in this case the recently rearranged *Igh* genes.

BMI1 is overexpressed in several hematologic malignancies, and its upregulation predicts poor prognosis in pediatric B cell acute lymphoblastic leukemia (B-ALL), the most common cancer in children ([@R35]; [@R38]). Work has shown that pre-BCR and downstream signaling promote the aggressiveness of certain subtypes of B-ALL and can be targeted to eliminate human and mouse B-ALL cells ([@R9]; [@R11]; [@R13]; [@R36]). It is therefore tempting to speculate that increased BMI1 expression promotes the inappropriate proliferation of B-ALL cells downstream of pre-BCR signaling in a process analogous to what we observed in normal developing B cells. If so, BMI1-dependent signaling might present a novel therapeutic approach to target B-ALL cell growth. Along these lines, a chemical inhibitor specific to BMI1 was identified and well tolerated in mice ([@R20]). Moreover, the inhibitor has been shown to be effective in various cancer cells ([@R20]; [@R48]).

Our study clarifies the function of BMI1 in early B cell development, revealing a critical role for BMI1 for the expression of rearranged *Igh* genes in pro-B cells and the clonal expansion of large pre-B cells, and adds to the expanding range of BMI1's function *in vivo*.

STAR★METHODS {#S11}
============

CONTACT FOR REAGENT AND RESOURCE SHARING {#S12}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Gregory David (<Gregory.David@nyulangone.org>).

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S13}
--------------------------------------

*Mx1-Cre*, *Bmi1*^*F*/+^, *Mb1-cre*, and *p53*^*F*/+^ mice were purchased from The Jackson Laboratory and have been described ([@R17]; [@R22]; [@R25]; [@R26]). *Bmi1*^+/−^ mice were a kind gift from Maarten van Lohuizen and have been described ([@R46]). *B1.8i* mice were a kind gift from Klaus Rajewsky and have been described ([@R42]). Animals were housed in specific pathogen-free conditions at the Skirball Animal Facility. Aged matched controls were used for *Bmi1* germline mutant mice whereas littermate controls were used for *Bmi1^F/F^* *Mb1-cre* mice. Female and male mice were used depending on availability. All mice were analyzed at 4-8 weeks of age. All animal experiments were done in accordance with the guidelines of the NYU School of Medicine Institutional Animal Care and Use Facility.

METHOD DETAILS {#S14}
--------------

### Mouse treatment {#S15}

For induction of Cre-mediated deletion of *loxP*-flanked *p53* alleles in the *Bmi1 p53 Mx1-Cre* animal cohort, poly(I:C) (InvivoGen) was administered by i.p. injection at 5μg kg^−1^ in PBS for 3 injections on alternating days at 3 weeks of age. Animals were analyzed two weeks following the last poly(I:C) injection.

### Flow cytometry analysis and cell sorting {#S16}

Single cell suspensions were derived from bone marrow (femur and tibia of both hind legs), spleen, thymus, and peripheral blood. Red blood cells were lysed with ACK lysis buffer. Cell counts were determined using a cell counter (Beckman Coulter) set to detect nuclei between 3.5uM and 10uM or manually with a hemocytometer. All cells were blocked with purified rat IgG (20ug ml^−1^) for 15 min on ice prior to antibody staining. The following antibodies were used for analysis (from Biolegend): anti-B220 (RA3-6B2), anti-CD19 (6D5), anti-CD4 (RM4-5), anti-CD8 (53-6.7), anti-CD11b (M1-70), anti-Gr1 (RB6-8C5), anti-TER119 (TER119), anti-CD25 (PC61), anti-IgM (RMM-1), anti-IgD (11-26c.2a), and anti-ckit (2B8). Cells were stained with primary antibodies for 30 min on ice. For intracellular staining of Igμ chain, cells were first stained for surface markers followed by fixation and permeabilization with BD Cytofix/Cytoperm for 30 min at room temperature. Cells were then incubated with an Igμ specific Fab fragment (Jackson ImmunoResearch) for 45 min on ice. PI (1ug ml^−1^), DAPI (500ng ml^−1^), 7aad (1ug ml^−1^), or Zombie fixable dye was added following staining for the exclusion of dead cells. Cells were identified based on the cell-surface phenotypes described in [Table S2](#SD1){ref-type="supplementary-material"}. Cells were analyzed on a LSRII (BD Biosciences) or sorted on an AriaI or AriaII (BD Biosciences). Data were analyzed with FlowJo software (FlowJo, LLC).

### RNA-sequencing {#S17}

RNA was isolated from FACS purified pro-B cells. RNA was harvested from 2 biological replicates using the RNeasy Micro Kit (QIAGEN). RNA quantification and quality was determined using an Aglient 1200 Bioanalyzer. Strand-specific libraries were prepared using the SMARTer low-input RNA kit. Libraries were sequenced on an Illumina HiSeq2500 using 50bp paired-end reads. Fastq files were aligned to mm9 using TopHat. Differential expression tests were done using the Cuffdiff module of Cufflinks against the Refseq annotation. We used an FDR \< 0.05 as a cutoff for significance. Gene set enrichment analysis was performed using log~2~ fold change as metric for ranking genes and 1,000 permutations. Gene sets used in this study were identified from the Molecular Signatures Database (Curated v5.0 and Hallmarks v5.0).

### Cell cycle analysis {#S18}

For cell cycle analysis of pre-B cells, cells were stained for surface markers, fixed and permeabilized with BD Cytofix/Cytoperm for 30 min at room temperature, and incubated with DAPI (10μg ml^−1^) and RNaseA(50μg ml^−1^) for 30 min at room temperature. For BrdU incorporation analysis of pre-B cells, mice were i.p. injected with 1mg BrdU and sacrificed 2 hr later. Cells were stained for surface markers and analyzed for BrdU incorporation as described using the BD PharMingen BrdU Flow Kit. Apoptotic cells were detected using the Annexin V Apoptosis Detection Kit (Biolegend) according to the manufacturer's instructions.

### RT-qPCR analysis {#S19}

RNA from sorted cell populations was isolated using the RNeasy Mini Kit (QIAGEN). Prior to reverse transcription, RNA was incubated with DNase I (Promega). RNA was subsequently converted into cDNA using either M-MLV reverse transcriptase (Promega) or Maxima reverse transcriptase (Thermo Scientific) according to the manufacturer's instructions, using an equal mix of oligo dT and random hexamers as primers. Real-time quantitative PCR (RT-qPCR) was performed on a Bio-rad iCycler using Maxima SYBR Green master mix (Thermo Scientific) according to the manufacturer's instructions. No-RT controls were included to ensure no genomic DNA contamination was present. All values were normalized to *Hprt* levels using the ΔCt method. RT-PCR primer pairs are shown in [Table S3](#SD1){ref-type="supplementary-material"}.

### Semiquantitative PCR analysis of VDJ~H~ joints {#S20}

Genomic DNA from sorted cell populations was isolated using the DNeasy Blood and Tissue kit (QIAGEN). *Igh* rearrangements were amplified as previously described ([@R12]). Briefly, serial dilutions of genomic DNA were amplified using a forward primer specific to either the D~H~, the V~H~7183 family, or the V~H~J558 family and a reverse primer specific to J~H3~. Primers specific to Cμ were used as a loading control. PCRs were run in the linear range and products were run on a 1.25% agarose gel. Primer pairs are shown in [Table S4](#SD1){ref-type="supplementary-material"}.

### Sub-clonal sequencing of VDJ~H~ joints {#S21}

Genomic DNA from sorted pro-B cells was isolated using the DNeasy Blood and Tissue kit (QIAGEN). *Igh* rearrangements were amplified using a promiscuous forward primer (MsVHe) (5′-GGGAATTCGAGGTGCAGCTGCAGGAGTCTGG-3′) that binds to genes within all V~H~ families and a reverse primer specific to J~H3~ (5′-GTCTAGATTCTCACAAGAGTCCGATAG ACCCTGG-3′). A high fidelity polymerase (Roche) was used to minimize point mutations during PCR amplification. The amplified product was run on a 1% agarose gel and the expected band size (\~450bp) was excised and purified. The purified DNA product was inserted into the pGEM-T easy vector (Promega) according to the manufacturers instructions. Subcloned DNA was column purified (QIAGEN) and sequenced using T7 primer (Macrogen). VDJ~H~ sequences were analyzed using the National Center for Biotechnology Information's IgBlast program.

### DNA FISH {#S22}

DNA FISH was performed with the probes BACs CT7-199M11 (3' *Igh*) and CT7-526A21 (5' *Igh*) labeled by nick translation. For each 22×22 mm coverslip, 1 μg of labeled BAC DNA, 10 μg of sheared salmon sperm DNA and 1 μg of Cot-1 (Life Technologies) were precipitated and resuspended in 16 μL of hybridization buffer (50% formamide/20% dextran sulfate/5X denhardt's solution). DNA FISH was carried out as previously described ([@R5]). Briefly, cells were adhered to poly-L-lysine coated coverslips for 10 min, fixed for 10 min at 22°C with 2% (wt/vol) paraformaldehyde/PBS and permeabilized for 10 min with 0.5% (vol/vol) Triton/ PBS. Coverslips were incubated with RNaseA (0.1 mg/ml in PBS, 30 min at 37°C), then re-permeabilized for 10 min at 0°C in 0.7% (vol/vol) Triton X-100 / 0.1 M HCl. Cells were then placed in 50% formamide/2XSSC for 1 hr at 22°C. Coverslips and resuspended probes were then placed at 75°C for 2 min, before probes were applied to coverslips, sealed onto slides with rubber cement, followed by incubation overnight at 37°C. Cells were then washed two times with 50%formamide/2xSSC at 42°C, two times with 2xSSC at 42°C and 1xSSC at 42°C, for 5 min each and were mounted in Prolong Gold (Life Technologies) containing 1.5 μg/ml DAPI.

### Confocal microscopy and analysis {#S23}

DNA FISH was imaged by confocal microscopy on a Leica SP5 AOBS system (Acousto-Optical Beam Splitter). Optical sections separated by 0.3 μm were collected and only cells with signals from both alleles were analyzed using ImageJ software (NIH). For distance measurements in DNA FISH, ImageJ was used to measure the center of mass of each focus and calculate intralocus distances.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S24}
---------------------------------------

Statistical analysis was performed using an unpaired Student's two-tailed t test. Differences in the distribution of intralocus distance between the 5' and 3' *Igh* FISH probes was compared using the Kolmogorov-Smirnov test. All experiments were performed in the number of biological replicates mentioned as n in the figure legends or shown as individual points in figures. N represents individual sequences for pro-B cell subclonal VDJ~H~ joint sequencing, individual cells for DNA FISH assessing *Igh* contraction, and individual animals for all other experiments. A p value \< 0.05 was considered statistically significant. All data were analyzed using GraphPad Prism software.

DATA AND SOFTWARE AVAILABILITY {#S25}
------------------------------

RNA-sequencing data were deposited at GEO and is available under accession GEO: GSE119422.
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======================

We are grateful to all members of the David laboratory for helpful discussions during the preparation of the manuscript. We wish to acknowledge the Skirball Institute of Biomolecular Medicine for hosting our laboratory following Hurricane Sandy. We thank the NYU Cytometry and Cell Sorting Core (supported in part by NIH/NCI support grant P30CA016087) for help with analysis and cell sorting. We thank the NYU Genome Technology Center (supported in part by NIH/NCI support grant P30CA016087) for help with RNA sequencing and bioinformatic analysis. This work was funded by the NIH (R01CA148639, R21CA155736, and R21CA206013 to G.D.), the Samuel Waxman Cancer Research Foundation (to G.D.), and a Feinberg NYU individual grant (to G.D.). D.J.C. was supported by a NIH MSTP training grant (T32GM007308), a predoctoral NIH/NCI training grant (T32CA009161), and a predoctoral NIH/NCI NRSA (F30CA203047).

SUPPLEMENTAL INFORMATION

Supplemental Information includes five figures and four tables and can be found with this article online at [https://doi.Org/10.1016/j.celrep.2018.12.030](https://doi.org/10.1016/j.celrep.2018.12.030).

DECLARATION OF INTERESTS

The authors declare no competing interests.

![BMI1 Is Required for the Pro-B Cell to Pre-B Cell Transition\
(A) Representative fluorescence-activated cell sorting (FACS) plots of developing B cells in the bone marrow of indicated mice. Shown is the frequency of each cell population in the bone marrow of indicated animals. Pro-B: B220^+^ CD19^+^ IgM^−^ IgD^−^ ckit^+^ CD25^−^. Pre-B: B220^+^ CD19^+^ IgM^−^ IgD^−^ ckit^+^ CD25^−^. Immature: B220^+^ CD19^+^ IgM^+^ IgD^−^. Mature: B220^+^ CD19^+^ IgM^+^ IgD^+^.\
(B) Frequency of indicated cell populations in the bone marrow of animals. Each point represents one animal; the line represents the mean. n = 6 for each genotype.\
(C) Frequency of indicated cell type in the peripheral blood of indicated animals. Each point represents one animal; the line represents the mean. n = 6 for *Bmi1*^+/+^ animals; n = 5 for *Bmi1*^−/−^ animals.\
(D) Frequency of B220^+^ cells in the spleens of indicated mice. Each point represents one animal; the line represents the mean. n = 4 for *Bmi1*^+/+^ animals; n = 7 for *Bmi1*^−/−^ animals.\
\*\*\*p \< 0.001, \*\*p \< 0.01. BM, bone marrow; PB, peripheral blood.\
See also [Figure S1](#SD1){ref-type="supplementary-material"}.](nihms-1517818-f0002){#F1}

![BMI1 Is Required for the Expression of Rearranged *Igh* Genes in Pro-B Cells\
(A) Representative FACS plot and quantification of Igμ chain-positive pro-B cells in *Bmi1*^+/+^ and *Bmi1*^−/−^ mice. Each point represents one animal; the line represents the mean. n = 4 for *Bmi1*^+/+^ animals; n = 5 for *Bmi1*^−/−^ animals.\
(B) Igμ MFI in Igμ-expressing pro-B cells. Each dot represents one animal; the line represents the mean. n = 4 for *Bmi1*^+/+^ animals; n = 5 for *Bmi1*^−/−^ animals.\
(C) Semiquantitative PCR analysis of genomic DNA from sorted *Bmi1*^+/+^ and *Bmi1*^−/−^ pro-B cells assessing the frequency of *Igh* locus rearrangement using either proximal (V~H~7183) or distal (V~H~J558) V~H~ gene segments. DNA from DP T was used as a negative control.\
(D) Frequency of proximal and distal V~H~ segments used in individually sequenced VDJ~H~ coding joints from sorted pro-B cells. VDJ~H~ joints were amplified using a promiscuous forward primer (MsVHe) and a reverse primer specific to J~H3~. n = 37 VDJ~H~ sequences for *Bmi1*^+/+^ pro-B cells, and n = 48 VDJ~H~ sequences for *Bmi1*^−/−^ pro-B cells sorted from 3 animals for each genotype.\
(E) qRT-PCR analysis of mRNA expression of rearranged *Igh* genes. DP T were used as negative controls. Data are shown as a Tukey box-and-whisker plot; the center line represents the median. n ≥ 5 for each genotype.\
\*\*\*p \< 0.001, \*\*p \< 0.01, \*p \< 0.05. MFI, median fluorescence intensity; DP T, double-positive thymocytes.\
See also [Figure S2](#SD1){ref-type="supplementary-material"}.](nihms-1517818-f0003){#F2}

![A pre-rearranged *Igh* Locus Restores B Cell Development to *Bmi1*^−/−^ Mice\
(A) Representative FACS plot of developing B cells in the bone marrow of indicated mice. Shown is the frequency of each cell population in the bone marrow of indicated animals.\
(B) Frequency of indicated cell type in the bone marrow of indicated mice. Data are shown as a Tukey box-and-whisker plot; the center line represents the median. n ≥ 5 for each genotype.\
(C) Frequency of B220^+^ cells in the spleen of indicated mice. Each point represents one animal; the line represents the mean. n ≥ 5 for each genotype.\
(D) Histogram showing the frequency of Igμ-positive pro-B cells from indicated animals. Igμ MFI in Igμ-expressing pro-B cells is indicated in the top right of each plot.\
\*\*\*p \< 0.001, \*p \< 0.05. BM, bone marrow; MFI, median fluorescence intensity.\
See also [Figure S3](#SD1){ref-type="supplementary-material"}.](nihms-1517818-f0004){#F3}

![BMI1 Prevents the Upregulation of p53 Signaling and Maintains Large Pre-B Cell Cycling\
(A) RNA sequencing (RNA-seq) MA (log ratio and mean average) plot of *Bmi1*^+/+^ versus *Bmi1*^−/−^ pro-B cells. Known targets of p53 are depicted in red.\
(B) qRT-PCR expression analysis of indicated genes from sorted pro-B cells of indicated mice. Each point represents one animal; the line represents the mean. n = 4 for *Bmi1*^+/+^ animals; n = 5 for *Bmi1*^−/−^ animals.\
(C) Frequency of apoptotic (as indicated by annexin V positivity) pro-B cells and pre-B cells of indicated mice. Each point represents one animal; the line represents the mean. n = 5 for each genotype.\
(D) Frequency of large pre-B cells present in the pre-B cell compartment of indicated mice. Each point represents one animal; the line represents the mean. n = 6 for each genotype.\
(E) FACS plot of developing B cells in the bone marrow of indicated mice. Shown is the frequency of each cell population in the bone marrow of indicated animals. Representative of 3 independent experiments.\
(F) Frequency of B220^+^ cells in the spleen and peripheral blood of indicated mice. Each point represents one animal; the line represents the mean. n = 3 for each genotype.\
\*\*\*p \< 0.001, \*\*p \< 0.01, \*p \< 0.05. PB, peripheral blood.\
See also [Figure S4](#SD1){ref-type="supplementary-material"} and [Table S1](#SD2){ref-type="supplementary-material"}.](nihms-1517818-f0005){#F4}

![BMI1 Regulates the Pro-B Cell to Pre-B Cell Transition in a Cell-Autonomous Manner\
(A) mRNA expression levels as determined by qRT-PCR of indicated genes from pro-B cells of indicated mice. Each point represents one animal; the line represents the mean. n = 3 for each genotype.\
(B) Representative FACS plot of developing B cells in the bone marrow of indicated mice. Shown is the frequency of each cell population in the bone marrow of indicated animals.\
(C) Frequency of developing B cells in the bone marrow of indicated mice. Each point represents one animal; the line represents the mean. n = 5 for *Bmi1^F/F^* animals; n = 6 for *Bmi1^F/F^* *Mb1-cre* animals.\
(D) Frequency of B220^+^ cells in the spleen and peripheral blood of indicated mice. Each point represents one animal; the line represents the mean. n = 4 for *Bmi1^F/F^* animals; n = 6 for *Bmi1^F/F^* *Mb1-cre* animals.\
(E) Frequency of Igμ-positive pro-B cells in indicated mice. Each point represents one animal; the line represents the mean. n = 5 for *Bmi1^F/F^* animals; n = 6 for *Bmi1^F/F^* *Mb1-cre* animals.\
(F) qRT-PCR analysis of gene expression of rearranged *Igh* genes in indicated mice. Data are shown as a box-and-whisker plot, with whiskers showing minimum and maximum values; the center line represents the median. n = 6 for each genotype.\
(G) qRT-PCR expression analysis of indicated genes from sorted pro-B cells from indicated mice. Data are shown as a box-and-whisker plot, with whiskers showing minimum and maximum values; the center line represents the median. n = 6 for each genotype.\
(H) Ratio of the frequency of pro-B cells to pre-B cells in the bone marrow of indicated mice. Data represent mean ± SEM; n = 3 for each genotype.\
(I) Frequency of B220^+^ cells in the spleen and peripheral blood of indicated mice. Data represent mean ± SEM; n = 3 for each genotype.\
\*\*p \< 0.01, \*p \< 0.05. BM, bone marrow; PB, peripheral blood.\
See also [Figure S5](#SD1){ref-type="supplementary-material"}.](nihms-1517818-f0006){#F5}

###### 

KEY RESOURCES TABLE

  REAGENT or RESOURCE                                                                                   SOURCE                          IDENTIFIER
  ----------------------------------------------------------------------------------------------------- ------------------------------- -----------------------------------------
  Antibodies                                                                                                                            
  Rat anti-mouse B220 -- APCCy7 (clone: RA3-6B2)                                                        Biolegend                       Cat\#103223; RRID: AB_313006
  Rat anti-mouse CD19 -- Pacific Blue (clone: 6D5)                                                      Biolegend                       Cat\#115526; RRID: AB_493341
  Rat anti-mouse ckit -- APC (clone: 2B8)                                                               Biolegend                       Cat\#105805; RRID: AB_313214
  Rat anti-mouse CD25 -- PE (clone: PC61)                                                               Biolegend                       Cat\#102007; RRID: AB_312856
  Rat anti-mouse IgM -- PECy7 (clone: RMM-1)                                                            Biolegend                       Cat\#406513; RRID: AB_10640069
  Rat anti-mouse IgD -- PerCP5.5 (clone: 11-26c.2a)                                                     Biolegend                       Cat\#405709; RRID: AB_1575115
  Rat anti-mouse CD4 -- FITC (clone: RM4-5)                                                             Biolegend                       
  Rat anti-mouse CD8 -- APCCy7 (clone: 53-6.7)                                                          Biolegend                       Cat\#100713; RRID: AB_312752
  Rat anti-mouse B220 -- Pacific Blue (clone: RA3-6B2)                                                  Biolegend                       Cat\#103230; RRID: AB_492877
  Rat anti-mouse Gr1 -- PE (clone: RB6-8C5)                                                             Biolegend                       Cat\#108407; RRID: AB_313372
  Rat anti-mouse TER119 -- PerCP (clone: TER119)                                                        Biolegend                       Cat\#116225; RRID: AB_893637
  Rat anti-mouse CD11b -- PECy7 (clone: M1-70)                                                          Biolegend                       Cat\#101215; RRID: AB_312798
  AffiniPure Fab Fragment Goat anti-mouse IgM, μ chain specific -- FITC                                 Jackson ImmunoResearch          Cat\#115-097-020; RRID: AB_2338618
  IgG from rat serum                                                                                    Sigma Aldrich                   Cat\#I4131; RRID: AB_1163627
  Bacterial and Virus Strains                                                                                                           
  NEB 5-alpha competent *E. coli*                                                                       New England Biolabs             Cat\#C2987I
  Chemicals, Peptides, and Recombinant Proteins                                                                                         
  DAPI                                                                                                  Sigma Aldrich                   Cat\#32670; CAS\#28718-90-3
  Critical Commercial Assays                                                                                                            
  FITC BrdU Flow Kit                                                                                    BD Biosciences                  Cat\#559619; RRID: AB_2617060
  FITC Annexin V Apoptosis Detection Kit                                                                Biolegend                       Cat\#640932
  Deposited Data                                                                                                                        
  Pro-B cell RNA-sequencing data                                                                        This paper                      GEO: GSE119422
  Experimental Models: Organisms/Strains                                                                                                
  Mouse: *Bmi1*^+/−^: FVB.129P2-*Bmi1^tm1Brn^*/MvlJ                                                     Maarten van Lohuizen ([@R46])   JAX: 024584
  Mouse: *B1.8*^+^: B6.129P2(C)-*Igh^tm2Cgn^*/J                                                         Klaus Rajewsky ([@R42])         JAX: 012642
  Mouse: *p53*^*F*/+^: B6.129P2-*Trp53^tm1Brn^*/J                                                       The Jackson Laboratory          JAX: 008462
  Mouse: *Mx1-cre*: B6.Cg-Tg(Mx1-cre)1Cgn/J                                                             The Jackson Laboratory          JAX: 003556
  Mouse: *Bmi1*^*F*/+^: *Bmi1^tm1.1Lees^*/J                                                             The Jackson Laboratory          JAX: 028572
  Mouse: *mb1-cre*: B6.C(Cg)-*Cd79a^tm1(cre)Reth^*/EhobJ                                                The Jackson Laboratory          JAX: 020505
  Oligonucleotides                                                                                                                      
  mRNA expression RT-PCR primer pairs, see [Table S3](#SD1){ref-type="supplementary-material"}          This paper                      N/A
  Primer pairs for analysis of VDJ~H~ joints, see [Table S4](#SD1){ref-type="supplementary-material"}   This paper                      N/A
  Software and Algorithms                                                                                                               
  FlowJo                                                                                                FlowJo, LLC                     <https://www.flowjo.com>
  Prism                                                                                                 Graphpad                        <https://www.graphpad.com>
  ImageJ                                                                                                NIH                             <https://imagej.nih.gov/ij/>
  NCBI IgBlast                                                                                          NIH                             <https://www.ncbi.nlm.nih.gov/igblast/>
  Other                                                                                                                                 
  Poly(I:C)                                                                                             InvivoGen                       Cat\#tlrl-picw
  BD Cytofix/Cytoperm                                                                                   BD Biosciences                  Cat\#554714
  Zoombie UV Fixable Viability Dye                                                                      Biolegend                       Cat\#423107
  Propidium Iodide Staining Solution                                                                    BD Biosciences                  Cat\#556463
  M-MLV Reverse Transcriptase                                                                           Promega                         Cat\#M1701
  Maxima Reverse Transcriptase                                                                          Thermo Scientific               Cat\#EP0741
  Maxima SYBR Green Master Mix                                                                          Thermo Scientific               Cat\#K0241
  Roche Expand High Fidelity PCR System                                                                 Roche                           Cat\#11732641001
  pGEM-T Easy Vector System                                                                             Promega                         Cat\#A1360
  RNeasy Micro Kit                                                                                      QIAGEN                          Cat\#74004
  RNeasy Mini Kit                                                                                       QIAGEN                          Cat\#74104
  DNAeasy Blood and Tissue Kit                                                                          QIAGEN                          Cat\#69504
  SMARTer low-input RNA kit                                                                             Clontech                        Cat\#634938

###### Highlights

-   BMI1 is required at the pro-B cell to pre-B cell transition in a cell-autonomous manner

-   BMI1 promotes the expression of newly rearranged *Igh* genes in pro-B cells

-   BMI1 prevents premature p53 activation and enables large pre-B cell proliferation
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